Literature DB >> 28685073

Factors favouring long-term survival following recurrence in ovarian cancer.

Hiroaki Soyama1, Masashi Takano2, Morikazu Miyamoto1, Tomoyuki Yoshikawa2, Tadashi Aoyama1, Tomoko Goto1, Junko Hirata1, Ayako Suzuki1, Hidenori Sasa1, Kenichi Furuya1.   

Abstract

The aim of the present study was to identify clinicopathological factors in long-term survivors following ovarian cancer recurrence. The patients who achieved longer survival after recurrence (n=18) and those who succumbed to the disease earlier (n=47) were identified and analyzed. There were no significant differences in age, performance status, stage distribution or histology between the two groups. Additionally, no significant difference was observed in progression-free survival after primary therapy. Multivariate analyses revealed that the predictive factors for long-term survival were i) secondary debulking surgery (OR=13.3; 95% CI: 1.39-226.7), ii) favourable response rate of second-line chemotherapy (OR=46.5; 95% CI: 1.84-313-4), and iii) ≥3 regimens after first recurrence (OR=9.01; 95% CI: 1.28-117.7). This study revealed that prolonged post-progression survival was associated with post-recurrence treatment. Therefore, appropriate selection of secondary debulking surgery and better chemotherapeutic response may lead to prolonged post-progression survival in recurrent ovarian cancer patients.

Entities:  

Keywords:  chemotherapy; ovarian cancer; overall survival; post-progression survival; recurrence; secondary debulking surgery

Year:  2017        PMID: 28685073      PMCID: PMC5492634          DOI: 10.3892/mco.2017.1266

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  20 in total

Review 1.  Systemic therapy for ovarian cancer: current status and new treatments.

Authors:  Robert F Ozols
Journal:  Semin Oncol       Date:  2006-04       Impact factor: 4.929

2.  External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer.

Authors:  Rafli van de Laar; Leon F A G Massuger; Toon Van Gorp; Joanna IntHout; Petra L M Zusterzeel; Roy F P M Kruitwagen
Journal:  Gynecol Oncol       Date:  2015-02-10       Impact factor: 5.482

3.  A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection.

Authors:  Wen-Juan Tian; Dennis S Chi; Jalid Sehouli; Claes G Tropé; Rong Jiang; Ali Ayhan; Gennaro Cormio; Yan Xing; Georg-Peter Breitbach; Elena Ioana Braicu; Catherine A Rabbitt; Halldis Oksefjell; Christina Fotopoulou; Hans-Gerd Meerpohl; Andreas du Bois; Jonathan S Berek; Rong-Yu Zang; Philipp Harter
Journal:  Ann Surg Oncol       Date:  2011-07-06       Impact factor: 5.344

4.  Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.

Authors:  Philipp Harter; Andreas du Bois; Maik Hahmann; Annette Hasenburg; Alexander Burges; Sibylle Loibl; Martina Gropp; Jens Huober; Daniel Fink; Willibald Schröder; Karsten Muenstedt; Barbara Schmalfeldt; Guenter Emons; Jacobus Pfisterer; Kerstin Wollschlaeger; Hans-Gerd Meerpohl; Georg-Peter Breitbach; Berno Tanner; Jalid Sehouli
Journal:  Ann Surg Oncol       Date:  2006-12       Impact factor: 5.344

5.  Identifying patients unlikely to benefit from further chemotherapy: a descriptive study of outcome at each relapse in ovarian cancer.

Authors:  Paul J Hoskins; Nhu Le
Journal:  Gynecol Oncol       Date:  2005-06       Impact factor: 5.482

6.  Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer.

Authors:  R Y Zang; Z Y Zhang; Z T Li; S M Cai; M Q Tang; J Chen; Q Liu
Journal:  Eur J Surg Oncol       Date:  2000-12       Impact factor: 4.424

7.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

8.  Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.

Authors:  Maurie Markman; Jonathan Markman; Kenneth Webster; Kristine Zanotti; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Journal:  J Clin Oncol       Date:  2004-08-01       Impact factor: 44.544

9.  Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: a retrospective analysis.

Authors:  M Petrillo; L Pedone Anchora; L Tortorella; F Fanfani; V Gallotta; M Pacciani; G Scambia; A Fagotti
Journal:  Gynecol Oncol       Date:  2014-06-05       Impact factor: 5.482

10.  Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

Authors:  Ignace B Vergote; Agustin Garcia; John Micha; Charles Pippitt; Johanna Bendell; Daniel Spitz; Nicholas Reed; Graham Dark; Paula M Fracasso; Emad N Ibrahim; Vincent A Armenio; Linda Duska; Chris Poole; Christine Gennigens; Luc Y Dirix; Abraham C F Leung; Carol Zhao; Raoudha Soufi-Mahjoubi; Gordon Rustin
Journal:  J Clin Oncol       Date:  2013-09-30       Impact factor: 44.544

View more
  1 in total

1.  Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer.

Authors:  Stephen Shuford; Christine Wilhelm; Melissa Rayner; Ashley Elrod; Melissa Millard; Christina Mattingly; Alina Lotstein; Ashley M Smith; Qi Jin Guo; Lauren O'Donnell; Jeffrey Elder; Larry Puls; S John Weroha; Xiaonan Hou; Valentina Zanfagnin; Alpa Nick; Michael P Stany; G Larry Maxwell; Thomas Conrads; Anil K Sood; David Orr; Lillia M Holmes; Matthew Gevaert; Howland E Crosswell; Teresa M DesRochers
Journal:  Sci Rep       Date:  2019-08-01       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.